Reference & AI

DAFMAN 44-197

Air Force

MILITARY DRUG DEMAND REDUCTION PROGRAM

Reviewed by Guilherme Correia, active-duty U.S. Air Force

DAFMAN 44-197, "MILITARY DRUG DEMAND REDUCTION PROGRAM", is a Department of the Air Force publication, dated September 5, 2023.

Published

September 5, 2023

OPR

AF/SG

Headquarters, Department of the Air Force

Official document

Open the PDF

on static.e-publishing.af.mil

DAFMAN 44-197 — index record

NumberDAFMAN 44-197
TitleMILITARY DRUG DEMAND REDUCTION PROGRAM
PublishedSeptember 5, 2023
Certified currentSeptember 5, 2023
Guidance memorandumFebruary 4, 2026
Office of primary responsibilityAF/SG
Issued byHeadquarters, Department of the Air Force
Status on the indexCurrent
Last index actionGM, February 4, 2026
Source indexAir Force e-Publishing
Index last readOctober 20, 2026

Copied from Air Force e-Publishing (index). The publication itself is the authority; this page does not summarize or interpret it. Verify the current edition on the index before acting.

From the publication itself

Text below is lifted mechanically from the official PDF (36 pages, read October 20, 2026) with no editing or interpretation. Quote the document, not this page.

Summary of changes, as printed

This interim change revises DAFMAN 44-197, Military Drug Demand Reduction Program, to be consistent with SAF/MR Memorandum, “Implementation of Executive Order 14168, Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government,” dated 4 February 2025. References from gender marker changed to sex. A margin bar (|) indicates newly revised material.

Contents

  1. Chapter 1—PROGRAM OVERVIEWp. 6
  2. Chapter 2—ROLES AND RESPONSIBILITIESp. 9
  3. Chapter 10—DRUG DEMAND REDUCTION (DDR) OUTREACH ACTIVITIESp. 60
  4. Attachment 1—GLOSSARY OF REFERENCES AND SUPPORTING INFORMATIONp. 63
All 56 contents entries
  1. Chapter 1—PROGRAM OVERVIEWp. 6
  2. 1.1. Overviewp. 6
  3. 1.3. Drug Demand Reduction Program Goals and Objectivesp. 7
  4. Chapter 2—ROLES AND RESPONSIBILITIESp. 9
  5. 2.1. Secretary of the Air Force for Manpower and Reserve Affairs (SAF/MR)p. 9
  6. 2.2. Air Force Surgeon General (AF/SG)p. 9
  7. 2.3. Department of the Air Force Drug Testing Program Manager (AFMRA/SG3L)p. 9
  8. 2.5. Air Force Drug Testing Laboratory (AFDTL, AFMRA/SG3L)p. 10
  9. 2.6. Deputy Chief of Staff for Manpower and Personnel (AF/A1)p. 10
  10. 2.7. Air Force Office of The Judge Advocate General (AF/JA)p. 10
  11. 2.8. Legal Advisor to the Air Force Drug Testing Laboratoryp. 11
  12. 2.9. Major Command Surgeon General (MAJCOM/SG)p. 11
  13. 2.10. Major Command Staff Judge Advocate (MAJCOM/SJA)p. 11
  14. 2.12. Installation/Wing Commanderp. 12
  15. 2.13. Installation Staff Judge Advocate (SJA)p. 13
  16. 2.14. Train the Trainersp. 13
  17. 2.15. Installation/Wing Drug Demand Reduction Program Manager (DDRPM)p. 14
  18. 2.16. Installation Drug Testing Program Administrative Manager (DTPAM)p. 15
  19. 2.17. Group, Squadron, Delta and Detachment Commanderp. 16
  20. 2.18. Trusted Agentp. 17
  21. 2.19. Observerp. 17
  22. 2.21. Medical Review Officer (MRO)p. 17
  23. 3.1. Qualifications of Personnelp. 19
  24. 3.2. Appointment of Personnelp. 21
  25. 3.3. Training of Personnelp. 22
  26. 4.2. Levels and Frequency of Testing for New Accessionsp. 26
  27. 4.3. Notification of Department of Air Force Members Selected for Testingp. 27
  28. 4.4. Inability to Provide a Urine Specimenp. 29
  29. 4.5. Procedures for Collecting Urine Specimensp. 30
  30. 4.6. Completion of the DD Form 2624p. 36
  31. 4.7. Instructions for Packaging of Urine Specimens for Shippingp. 38
  32. 4.10. Packaging and Shipping Urine Specimens Collected Using Single Test Kitsp. 42
  33. 4.11. Acceptable Modes of Transportationp. 43
  34. 5.1. Periodic Inspections of Collection Sitesp. 44
  35. 5.2. Collection Site Inspection Reportp. 45
  36. 6.2. Storage and Destruction of Positive Specimensp. 46
  37. 7.1. Overviewp. 48
  38. 7.2. Drug Results That Do Not Require MRO Reviewp. 48
  39. 7.3. Drug Results That Require MRO Reviewp. 48
  40. 7.4. Positive Result Notification for Drugs that Do Not Require MRO Reviewp. 49
  41. 7.5. Positive Result Notification for Drugs that Require MRO Reviewp. 49
  42. 7.6. Positive Result Notification for ANG and AFR only:p. 50
  43. 7.7. Reporting Results or Invalid Specimensp. 51
  44. 7.8. Legal Requests for Urinalysis Testing Datap. 51
  45. 8.1. Requests for Retests of Specimensp. 52
  46. 8.2. Requests for Steroid Testingp. 53
  47. 8.3. Requests for Special Testingp. 54
  48. 9.1. Drug Testing Guidelines and Regulationsp. 56
  49. 9.2. Commander’s Periodic Meetingsp. 56
  50. 9.3. Drug Testing Program Metricsp. 57
  51. 9.4. Use and Disposition of Drug Testing Resultsp. 58
  52. Chapter 10—DRUG DEMAND REDUCTION (DDR) OUTREACH ACTIVITIESp. 60
  53. 10.1. Community Outreach Activitiesp. 60
  54. 10.2. Community Outreach Fundingp. 60
  55. 11.1. Budget Management for MAJCOM and Installation DDR Programsp. 61
  56. Attachment 1—GLOSSARY OF REFERENCES AND SUPPORTING INFORMATIONp. 63

Other DAFMAN publications nearby in the series

204 DAFMAN records on the Air Force index. Search the full index.

Works of the United States Government are not subject to copyright (17 U.S.C. § 105). This site is not affiliated with the Department of the Air Force or any government agency.

Air Force index

REF: DAFMAN 44-197, effective September 5, 2023

Air Force e-Publishing — DAFMAN 44-197

This is an index record, not the publication. The official PDF is the authority; verify the current edition before acting.

Reviewed by Guilherme Correia · Military Toolkit editorial

Open the official PDF